<DOC>
	<DOCNO>NCT00838513</DOCNO>
	<brief_summary>The purpose study determine whether eculizumab safe effective treatment adult patient plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome ( aHUS ) .</brief_summary>
	<brief_title>Open Label Controlled Trial Eculizumab Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome ( aHUS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Azotemia</mesh_term>
	<mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
	<mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
	<criteria>Inclusion Critera : 1 . Male female patient ' ≥18 year age diagnose Atypical HemolyticUremic Syndrome ( aHUS ) . 2 . Patients must receive PT aHUS must observe receive ≥ 1 PT treatment every two week 3 PT treatments/week ( unchanged frequency ) least 8 week first dose IP . 3 . Platelet Count PrePT Baseline SetPoint ( collect hour Qualifying PT Episode ) within 75 % average PrePT platelet count collect Screening Observation Period . 4 . Known complement regulatory protein genetic abnormality . 5 . Lactate dehydrogenase ( LDH ) level screen onset current aHUS episode ≥ ULN . If LDH normal screening , marker indicative ongoing hemolysis haptoglobin , schistocytes evaluate discussed Sponsor . 6 . Creatinine level ≥ ULN age . 7 . Female patient childbearing potential must practice effective , reliable medically approve contraceptive regimen entire duration study , include followup period 5 month follow eculizumab treatment discontinuation . 8 . Able give write informed consent . 9 . Able willing comply study procedure . 1 . TTP , ( defined ADAMTS13 activity &lt; 5 % ) historical observation ( prior initiation plasma therapy ) test screen visit central laboratory . 2 . Malignancy within 5 year screen . 3 . Typical HUS ( Shiga toxin + ) . 4 . Known HIV infection . 5 . Identified drug exposurerelated HUS . 6 . Infectionrelated HUS . 7 . HUS relate bone marrow transplant . 8 . HUS related vitamin B12 deficiency . 9 . Patients confirm diagnosis sepsis . 10 . Presence suspicion active untreated systemic bacterial infection , opinion Investigator confound accurate diagnosis aHUS impedes ability manage aHUS disease . 11 . Pregnancy lactation . 12 . Unresolved meningococcal disease . 13 . Known Systemic Lupus Erythematosus ( SLE ) antiphospholipid antibody positivity syndrome . 14 . Any medical psychological condition , opinion investigator , could increase patient 's risk participate study confound outcome study . 15 . Patients receive previous treatment eculizumab . 16 . Patients receive IVIg within 8 week Rituximab therapy within 12 week screen visit . 17 . Patients receive immunosuppressive therapy steroid , mTOR inhibitor tacrolimus exclude unless : [ 1 ] part establish posttransplant antirejection regime , [ 2 ] patient confirm antiCFH antibody require immunosuppressive therapy , [ 3 ] dose medication unchanged least 4 week prior screen period throughout Observation Period [ 4 ] patient experience acute aHUS relapse immediately transplant . 18 . Patients receive Erythrocyte Stimulating Agents ( ESAs ) unless already stable dose least 4 week prior screen period , washout period least 2 week last dose ESA therapy . 19 . Participation investigational drug trial exposure investigational agent , device , procedures begin 4 week prior screen throughout entire trial . 20 . Hypersensitivity eculizumab , murine proteins one excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>aHUS</keyword>
</DOC>